{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.585","value":"-3.12"},{"groupId":"OG001","spread":"22.349","value":"-5.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.708","value":"-2.96"},{"groupId":"OG001","spread":"14.081","value":"1.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Sexual Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.496","value":"-5.30"},{"groupId":"OG001","spread":"18.540","value":"-3.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.132","value":"-2.41"},{"groupId":"OG001","spread":"12.631","value":"-2.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Breast Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.536","value":"5.65"},{"groupId":"OG001","spread":"15.536","value":"3.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Systemic Therapy Side Effects"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.982","value":"2.65"},{"groupId":"OG001","spread":"31.428","value":"0.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"title":"Breast Satisfaction"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.316","value":"-0.14"},{"groupId":"OG001","spread":"12.458","value":"0.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Endocrine Therapy Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.721","value":"4.67"},{"groupId":"OG001","spread":"18.232","value":"12.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Skin Mucosis Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.831","value":"3.66"},{"groupId":"OG001","spread":"15.969","value":"2.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"title":"Endocrine Sexual Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.979","value":"-3.03"},{"groupId":"OG001","spread":"20.101","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.161","value":"8.72"},{"groupId":"OG001","spread":"29.022","value":"11.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Future Perspective"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.500","value":"2.47"},{"groupId":"OG001","spread":"40.825","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Being Upset By Hair Loss"}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"description":"EORTC QLQ-BR45 is an updated version of the BR23. Self-administered instrument includes original 23-items yielding 5 multi-item scores (body image, sexual functioning, arm symptoms, breast symptoms, and systemic therapy side effects). Additional 22 items yield 4 additional multi-item scales (breast satisfaction, endocrine therapy symptoms, skin mucosis symptoms, and endocrine sexual symptoms). Single items assess sexual enjoyment, future perspective and being upset by hair loss. Items are scored on a 4-point verbal rating scale: 1: not at all, 2: a little, 3: quite a bit, and 4: very much; higher score: better level of functioning or greater degree of symptoms. Scores of these scales were averaged from scores of component items, transformed, and ranged from 0 to 100; higher scores for functioning scales or items indicate better functioning, whereas higher scores for symptom scales or items represent a higher level of symptoms. Baseline:last observed measurement prior to randomization.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received T-DXd 5.4 mg/kg via IV infusion every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG000","title":"T-DXd"},{"description":"Participants received Investigator's choice single-agent chemotherapy (capecitabine 1000 or 1250 mg/m\\^2 orally twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles, paclitaxel 80 mg/m\\^2 via IV infusion qw in 3-week cycles or nab-paclitaxel 100 mg/m\\^2 via IV infusion qw for 3 weeks followed by 1-week rest period in 4-week cycles) until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEAN","populationDescription":"The ITT population included all randomized participants. Only participants with data collected in specified categories are reported.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and Week 58","title":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Breast Module 45 (BR45) Scale Score at Week 58","type":"SECONDARY","unitOfMeasure":"score on a scale"}